PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) HETERODIMERS REDUCE SERUM LDL-CHOLESTEROL (LDL-C) LEVELS IN MAINTENANCE HEMODIALYSIS (HD) PATIENTS ASSOCIATED WITH DYSLIPIDEMIA CHARACTERIZED BY INCREASED TRIGLYCERIDE-RICH LIPOPROTEINS

被引：0
|
作者：
Kihara, Emi [1 ]
Arita, Kazuko [1 ]
Hamamoto, Misuzu [1 ]
Maeda, Katsutoshi [1 ]
Oda, Hiroaki [1 ]
Doi, Shigehiro [2 ]
Masaki, Takao [2 ]
机构：
[1] Oda Med Clin, Hiroshima, Japan
[2] Hiroshima Univ Hosp, Dept OF Nephrol, Hiroshima, Japan
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2012年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
引用
收藏
页码：215 / 216
页数：2
相关论文
共 35 条
  • [21] Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus
    Kosmas, Constantine E.
    Sourlas, Andreas
    Bouza, Kyriaki V.
    DeJesus, Eddy
    Silverio, Delia
    Montan, Peter D.
    Guzman, Eliscer
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (07)
  • [22] Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis
    Feder, Susanne
    Wiest, Reiner
    Weiss, Thomas S.
    Aslanidis, Charalampos
    Schacherer, Doris
    Krautbauer, Sabrina
    Liebisch, Gerhard
    Buechler, Christa
    LIPIDS IN HEALTH AND DISEASE, 2021, 20 (01)
  • [23] Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis
    Susanne Feder
    Reiner Wiest
    Thomas S. Weiss
    Charalampos Aslanidis
    Doris Schacherer
    Sabrina Krautbauer
    Gerhard Liebisch
    Christa Buechler
    Lipids in Health and Disease, 20
  • [24] Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population
    Hamamura, Hitoshi
    Adachi, Hisashi
    Enomoto, Mika
    Fukami, Ako
    Nakamura, Sachiko
    Nohara, Yume
    Morikawa, Nagisa
    Sakaue, Akiko
    Toyomasu, Kenta
    Yamamoto, Maki
    Fukumoto, Yoshihiro
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2021, 28 (04) : 329 - 337
  • [25] Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
    Fitzgerald, Kevin
    Frank-Kamenetsky, Maria
    Shulga-Morskaya, Svetlana
    Liebow, Abigail
    Bettencourt, Brian R.
    Sutherland, Jessica E.
    Hutabarat, Renta M.
    Clausen, Valerie A.
    Karsten, Verena
    Cehelsky, Jeffrey
    Nochur, Saraswathy V.
    Kotelianski, Victor
    Horton, Jay
    Mant, Timothy
    Chiesa, Joseph
    Ritter, James
    Munisamy, Malathy
    Vaishnaw, Akshay K.
    Gollob, Jared A.
    Simon, Amy
    LANCET, 2014, 383 (9911): : 60 - 68
  • [26] TO COMPARE THE "REAL WORLD" EFFICACY OF PROPROTEIN CONVERTASE SUBTILISIN-KEXIN TYPE 9 (PCSK-9) INHIBITORS ALIROCUMAB VERSUS EVOLOCUMAB ON LDL LOWERING IN PATIENTS PRESENTING WITH DYSLIPIDEMIA: A SINGLE CENTER EXPERIENCE
    Banga, S.
    Pendyala, S.
    Kizhakekuttu, T. J.
    CARDIOLOGY, 2018, 140 : 116 - 116
  • [27] The proprotein convertase subtilisin-kexin type 9 (PCSK9) R46L variant is associated with reduced serum low-density lipoprotein cholesterol in the Italian population
    Ouga, Stefano
    Guella, Ilaria
    Asselta, Rosanna
    Rimoldi, Valeria
    Peyvandi, Flora
    Fetiveau, Raffaella
    Merlini, Pier Angelica
    Kathiresan, Sekar
    Ardissino, Diego
    Mannucci, Pier Mannuccio
    CIRCULATION, 2007, 116 (16) : 608 - 608
  • [28] ELEVATION OF SERUM PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) CONCENTRATIONS AND ITS CORRELATION WITH C-REACTIVE PROTEIN, BUT NOT ATHEROGENIC LIPIDS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Fang, C.
    Huang, L.
    Luo, T.
    Chen, X.
    Lin, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1219 - 1219
  • [29] Proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer
    Ozkan, Cigdem
    Akturk, Mujde
    Altinova, Alev Eroglu
    Cerit, Ethem Turgay
    Gulbahar, Ozlem
    Yalcin, Mehmet Muhittin
    Cakir, Nuri
    Toruner, Fusun Balos
    ENDOCRINE JOURNAL, 2015, 62 (12) : 1091 - 1099
  • [30] FoxO3 Transcription Factor and Sirt6 Deacetylase Regulate Low Density Lipoprotein (LDL)-cholesterol Homeostasis via Control of the Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Gene Expression
    Tao, Rongya
    Xiong, Xiwen
    DePinho, Ronald A.
    Deng, Chu-Xia
    Dong, X. Charlie
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (41) : 29252 - 29259
1234